Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.48B P/E - EPS this Y 12.70% Ern Qtrly Grth -
Income -519.21M Forward P/E -10.18 EPS next Y -13.10% 50D Avg Chg 25.00%
Sales 742k PEG - EPS past 5Y - 200D Avg Chg 36.00%
Dividend N/A Price/Book 3.66 EPS next 5Y - 52W High Chg -
Recommedations 1.50 Quick Ratio 15.10 Shares Outstanding 167.04M 52W Low Chg 92.00%
Insider Own 2.14% ROA -24.95% Shares Float 153.31M Beta 1.43
Inst Own 104.25% ROE -40.73% Shares Shorted/Prior 17.17M/16.84M Price 32.78
Gross Margin - Profit Margin - Avg. Volume 1,021,824 Target Price 60.08
Oper. Margin -77,524.66% Earnings Date Nov 4 Volume 3,063,320 Change 4.06%
About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc. News
11/09/24 Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight
11/07/24 Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
11/06/24 Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
11/05/24 Revolution Medicines to Participate in Upcoming Investor Conferences
10/30/24 Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
10/25/24 Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
10/23/24 Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
03:05 PM Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
10/07/24 Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
09/14/24 Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks
08/09/24 Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)
08/08/24 Q2 2024 Revolution Medicines Inc Earnings Call
08/07/24 Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
08/01/24 Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
07/31/24 Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
07/15/24 Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
07/11/24 Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
07/10/24 Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
07/08/24 Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
06/20/24 Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)
RVMD Chatroom

User Image Quantumup Posted - 2 days ago

Jefferies initiated Erasca Inc ( $ERAS) at a Buy rating and a $6 price target. Jefferies told investors in its research note: "We see appeal in $ERAS's valuation supported by early but pot'ly best-in-class pan-RAS and pan-KRAS-targeted txs, given the massive market opty ( $RVMD mkt cap of ~$9B) and derisked MOA, based on data from $RVMD's RMC-6236. Add'ly, $ERAS preclin data look promising and are on-par/better than RMC-6236. ERAS is also in ph.III NRASmut melanoma w/ naporafenib + trametinib; although mkt opty could be smaller vs RAS, the study is derisked given prior ph.I&Il data." $nvs $mrk $dawn

User Image Quantumup Posted - 4 days ago

BofA reit $RVMD Buy/$80. BofA's '6236 Base Case Peak Sale est=$11.4B on 8% penetration; 60% PoS: Exhibit 3 =*both, a Cross-trial comparison for 2L NSCLC Tx options and Minimum bar set by chemo combos, targeted therapy bar set by sotorasib/adagrasib: $MRK $RHHBY $BMY $AMGN SNY

User Image hope_my_calls_print Posted - 5 days ago

$RVMD god damn't. I really didn't want to be right about this.

User Image hope_my_calls_print Posted - 6 days ago

$RVMD hate to say it for the health of my gains, but called it. think we're gonna slide back to 50-55 area before this settles down. No worries, good opportunity to load up on the LEAPs

User Image Irish_lass Posted - 1 week ago

$RVMD Hmmmm

User Image Irish_lass Posted - 1 week ago

$RVMD Watching the volume

User Image Irish_lass Posted - 1 week ago

$RVMD

User Image hope_my_calls_print Posted - 1 week ago

$RVMD i'm still really optimistic on the data and the company, but holy fucking crap the chart feels overextended to me. Either the big one is coming (BO) or we're gonna fall back to 50-55 range. We spent a grand total of 25 days in the 50s before breaking to 60???

User Image RoyMunson69 Posted - 1 week ago

$RVMD

User Image IN0V8 Posted - 1 week ago

$RVMD Opportunity JP Morgan raises target price to $63 from $54 Piper Sandler raises target price to $70 from $57 H.C. Wainwright raises target price to $64 from $62

User Image EmSol Posted - 1 week ago

$RVMD it’s coming.

User Image Irish_lass Posted - 2 weeks ago

$RVMD Excellent call with more to look forward to this quarter. Looking forward to the upcoming data on their monotherapy and combo. with pembrolizumab in NSCLC.

User Image Irish_lass Posted - 2 weeks ago

$RVMD https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-third-quarter-2024-financial

User Image hope_my_calls_print Posted - 2 weeks ago

$RVMD chart is unbefuckinglievable but I'm a bit worried we need a pull back to 50-55 range and consolidate a bit. 10B MC is starting to feel like a little rich.

User Image ThomasScher875 Posted - 2 weeks ago

$RVMD As an investor, it's frustrating to see the other company unveiling advanced tech while our side is still ironing out basic issues.

User Image RonIsWrong Posted - 2 weeks ago

$RVMD ER tomorrow...

User Image smartkarma Posted - 2 weeks ago

$RVMD | 2023 High Conviction Update: Revolution Medicines, Time To Take Profits? "I remove Revolution Medicines stock from my high conviction list of ideas due to achieving a $55.00 price target and full valuation relative to peers." - Andrei Zakharov Read more: https://www.smartkarma.com/insights/2023-high-conviction-update-revolution-medicines-time-to-take-profits

User Image RonIsWrong Posted - 2 weeks ago

$RVMD a little bit higher now

User Image FlynancialAnalyst Posted - 10/31/24

A ton of noteworthy action in biotech $XBI today $RVMD $BLTE $CORT $UTHR SPRY, CRNX, CNTA, JANX, KRYS, VERA, MRUS, NRIX, AXSM

User Image EmSol Posted - 10/31/24

$GILD $RVMD thank god I have both today all my other position are red red red

User Image Irish_lass Posted - 10/31/24

$RVMD Couldn’t help it 😂

User Image Doozio Posted - 10/31/24

N it appears this $rave is just getting going with a Thursday 🐑 🎁 in da FUTure of 🧠⏰ as $rvmd goes 🧠⏰♾️

User Image Himel92 Posted - 10/31/24

The Last month Performance for $RVMD Opening Price: $45.32 Closing Price: $50.50 Highest Price: $51.10 Lowest Price: $43.97 Percentage Change: 11.43% Data provider: AITX

User Image RonIsWrong Posted - 10/31/24

$RVMD there

User Image Irish_lass Posted - 10/31/24

$RVMD

User Image RonIsWrong Posted - 10/30/24

$RVMD 👀👀 Unusual options activity today call sweeper on the Jan $55 calls - 3200 contracts or so with a smaller $46 Put hedge too - 420 contracts. calls are costing around $1.8M puts are costing 168K note plenty of calls and puts on the Nov OI (I posted both as images, but I think you only see one on the app, for now)

User Image EmSol Posted - 10/29/24

$RVMD $GILD buying for $85

User Image RonIsWrong Posted - 10/29/24

$RVMD a little bump

User Image RonIsWrong Posted - 10/29/24

$RVMD some unusual options activity today about 950 Nov $50 calls bought between 1.70 and 1.85 or so. earnings play, I assume and yesterday: Guggenheim analyst Michael Schmitz maintains Revolution Medicines(RVMD) with a Buy and raises the price target from $72 to $82. Oppenheimer analyst Jay Olson maintains Revolution Medicines(RVMD) with a Outperform and raises the price target from $55 to $60.

User Image Thestocktraderhubzee Posted - 10/28/24

WATCHLIST OCT 29 2024 $LOGI Loop Capital Maintains Hold on Logitech International, Lowers Price Target to $81 $RVMD Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $82 $DGX Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $165 $BFH TD Cowen Maintains Hold on Bread Finl Hldgs, Raises Price Target to $50 $GBCI Piper Sandler Maintains Neutral on Glacier Bancorp, Raises Price Target to $45

Analyst Ratings
Barclays Overweight Sep 27, 24
HC Wainwright & Co. Buy Aug 12, 24
JP Morgan Overweight Aug 8, 24
Wedbush Outperform Aug 8, 24
Needham Buy Aug 8, 24
Barclays Overweight Jul 18, 24
Oppenheimer Outperform Jul 16, 24
B of A Securities Buy Jul 16, 24
HC Wainwright & Co. Buy Jul 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anders Jack Chief Financial Offi.. Chief Financial Officer Dec 18 Sell 25.9018 1,775 45,976 76,416 12/20/23
GOLDSMITH MARK A See Remarks See Remarks Dec 18 Sell 25.9018 8,165 211,488 376,167 12/20/23
Cislini Jeff General Counsel General Counsel Dec 18 Sell 25.9017 1,229 31,833 37,284 12/20/23
Kelsey Stephen Michael See Remarks See Remarks Dec 18 Sell 25.9016 2,088 54,083 271,633 12/20/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Dec 15 Sell 26.27 7,993 209,976 101,467 12/19/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Dec 15 Option 4.09 5,000 20,450 109,460 12/19/23
Cislini Jeff General Counsel General Counsel Nov 20 Sell 21.6966 1,500 32,545 38,513 11/20/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Oct 25 Option 0.54 7,500 4,050 104,460 10/25/23
GOLDSMITH MARK A See Remarks See Remarks Oct 24 Option 0.49 35,000 17,150 384,332 10/24/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Oct 23 Option 3.39 24,524 83,136 78,191 10/23/23
Cislini Jeff General Counsel General Counsel Sep 28 Sell 28.58 2,000 57,160 40,013 10/02/23
GOLDSMITH MARK A See Remarks See Remarks Sep 01 Option 0.83 30,000 24,900 387,386 09/06/23
GOLDSMITH MARK A See Remarks See Remarks Sep 01 Sell 35.04 40,000 1,401,600 35,424 09/06/23
Weber Barbara Director Director Sep 01 Sell 35.07 15,000 526,050 15,825 09/06/23
Weber Barbara Director Director Sep 01 Option 2.93 15,000 43,950 30,825 09/06/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Sep 01 Sell 35.05 20,000 701,000 55,094 09/06/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Sep 01 Option 2.68 20,000 53,600 75,094 09/06/23
Cislini Jeff General Counsel General Counsel Jul 31 Sell 26.02 1,500 39,030 43,227 08/01/23
Horn Margaret A See Remarks See Remarks Mar 17 Sell 21.78 1,230 26,789 100,062 03/21/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Mar 17 Sell 21.78 665 14,484 55,233 03/21/23
Kelsey Stephen Michael See Remarks See Remarks Mar 17 Sell 21.78 1,230 26,789 326,369 03/21/23
Wang Xiaolin See Remarks See Remarks Mar 17 Sell 21.78 714 15,551 58,813 03/21/23
Schroeder Thilo Director Director Mar 07 Buy 21.32 650,000 13,858,000 1,553,134 03/10/23
GOLDSMITH MARK A See Remarks See Remarks Feb 22 Option 0.49 45,000 22,050 251,872 02/23/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Oct 31 Sell 20.4053 17,767 362,541 17,767 11/02/22
Wang Xiaolin See Remarks See Remarks Sep 19 Sell 19.0426 735 13,996 31,235 09/21/22
Kelsey Stephen Michael See Remarks See Remarks Sep 19 Sell 19.0426 1,267 24,127 288,819 09/21/22
Horn Margaret A See Remarks See Remarks Sep 19 Sell 19.0426 1,267 24,127 62,512 09/21/22
Anders Jack Chief Financial Offi.. Chief Financial Officer Sep 19 Sell 19.0426 449 8,550 29,956 09/21/22
GOLDSMITH MARK A See Remarks See Remarks Aug 11 Option 0.49 10,000 4,900 206,872 08/15/22
GOLDSMITH MARK A See Remarks See Remarks Aug 09 Option 0.49 10,336 5,065 196,872 08/10/22
Schroeder Thilo Director Director Jul 22 Buy 20.00 250,000 5,000,000 1,221,315 07/26/22
Kim Lorence H. Director Director Jul 22 Buy 20.00 50,000 1,000,000 60,500 07/25/22
Wang Xiaolin See Remarks See Remarks Jun 17 Sell 17.7495 665 11,803 31,970 06/22/22
Kelsey Stephen Michael See Remarks See Remarks Jun 17 Sell 17.7495 1,145 20,323 290,086 06/22/22
Horn Margaret A See Remarks See Remarks Jun 17 Sell 17.7495 1,145 20,323 63,779 06/22/22
Anders Jack See Remarks See Remarks Jun 17 Sell 17.7495 406 7,206 20,405 06/22/22
Third Rock Ventures III, L.P. 10% Owner 10% Owner Jun 08 Sell 20.25 419,901 8,502,995 5,104,130 06/10/22
Exter Neil Director Director Jun 08 Sell 0.00 06/10/22
Schroeder Thilo Director Director Mar 25 Buy 24.85 42,725 1,061,716 971,315 03/29/22
Schroeder Thilo Director Director Mar 22 Buy 23.48 232,364 5,455,907 928,590 03/24/22
Schroeder Thilo Director Director Mar 17 Buy 20.08 168,051 3,374,464 696,226 03/21/22
Horn Margaret A See Remarks See Remarks Mar 17 Sell 18.6145 321 5,975 63,987 03/21/22
Kelsey Stephen Michael See Remarks See Remarks Mar 17 Sell 18.6162 321 5,976 290,294 03/21/22
Wang Xiaolin See Remarks See Remarks Mar 17 Sell 18.6142 240 4,467 31,698 03/21/22
GOLDSMITH MARK A See Remarks See Remarks Mar 17 Sell 18.6141 1,023 19,042 185,599 03/21/22
Anders Jack See Remarks See Remarks Mar 17 Sell 18.6162 159 2,960 19,875 03/21/22
Schroeder Thilo Director Director Mar 10 Buy 20.91 43,510 909,794 528,175 03/14/22
Schroeder Thilo Director Director Mar 07 Buy 19.14 246,438 4,716,823 484,665 03/09/22
Schroeder Thilo Director Director Feb 18 Buy 23.17 1,088,227 25,214,220 238,227 03/04/22